Tarsus Pharmaceuticals, Inc. — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023. Financial statements are unaudited. Amounts are in U.S. dollars; financial statement amounts are generally in millions unless stated otherwise.
Business context
Tarsus is a commercial-stage biopharmaceutical company developing and commercializing therapeutics, beginning with eye care. FDA approved XDEMVY (lotilaner ophthalmic solution 0.25%) for Demodex blepharitis on July 24, 2023; the company launched it on August 24 and recorded its first product sales in Q3. Pipeline programs include TP-03 for meibomian gland disease (MGD), TP-04 for rosacea, and TP-05 for Lyme disease prophylaxis and community malaria reduction.
Key financial results
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Total revenue | $1.871 | $0 | $4.371 | $15.816 |
| Product sales, net | $1.653 | $0 | $1.653 | $0 |
| Operating expenses | $42.806 | $22.906 | $103.079 | $63.467 |
| Research and development | $12.105 | $10.912 | $37.007 | $32.596 |
| Selling, general and administrative | $30.324 | $11.994 | $65.695 | $30.316 |
| Net loss | $39.148 | $22.511 | $93.991 | $48.492 |
| Basic and diluted loss per share | $1.28 | $0.84 | $3.35 | $2.03 |
| Net cash used in operating activities | Not stated for quarter | Not stated for quarter | $78.158 | $38.156 |
Q3 cost of sales was $0.377 million against $1.653 million of product sales, implying an early-launch gross margin of approximately 77%. This is not necessarily representative: before FDA approval, manufacturing costs were expensed in R&D rather than inventory, and the filing says initial cost of sales will reflect lower unit costs until that inventory is sold. Revenue was net of rebates, chargebacks, discounts, and other adjustments.
At September 30, cash and cash equivalents were $226.672 million, marketable securities $20.213 million, and total cash, cash equivalents and marketable securities $246.9 million. Current assets were $259.277 million and current liabilities $23.249 million. Total liabilities were $54.668 million; term-loan principal was $30.0 million ($29.708 million net carrying amount). Accumulated deficit was $202.754 million.
Changes versus comparable periods
- Q3 revenue began with XDEMVY product sales; nine-month license and collaboration revenue fell to $2.718 million from $15.816 million, primarily reflecting lower China out-license revenue. The 2022 period included substantially more China out-license revenue.
- Q3 net loss widened by $16.637 million year over year; nine-month net loss widened by $45.499 million. SG&A increased substantially as Tarsus expanded staffing and commercial launch, marketing, and infrastructure activity.
- Nine-month operating cash use increased to $78.158 million from $38.156 million, reflecting higher operating costs and the timing of receipts. Investing cash flow was positive $122.754 million, largely due to $156.920 million of investment maturities; financing provided $110.416 million, including public-offering proceeds and loan draws.
- Cash and cash equivalents increased by $155.012 million during the first nine months. The August 2023 follow-on offering generated approximately $99.4 million net proceeds; shares outstanding increased to 33.104 million from 26.727 million at year-end 2022.
Outlook, risks and unusual items
- Management expects operating losses to continue and states existing capital resources are expected to fund projected operating expenses for at least 12 months from the filing date. This estimate depends on assumptions about revenue, expenses, and debt availability; additional capital may be needed.
- Management expected topline results from the TP-03 Ersa MGD Phase 2a trial in Q4 2023, TP-04 Galatea rosacea Phase 2a trial in Q1 2024, and TP-05 Carpo Lyme prevention Phase 2a trial in Q1 2024; Carpo timing had shifted due to enrollment delays.
- Management reported active payer contracting discussions, with commercial coverage potentially secured sequentially during 2024 and Medicare coverage in 2025. These are expectations, not guarantees.
- Credit facility: $30 million principal outstanding, floating interest at the greater of prime plus 4.45% (capped at 11.45%) or 8.45%, and interest-only payments expected through February 2026. Up to $125 million of additional tranched availability was described, subject to conditions, revenue milestones, lender approval, and draw deadlines.
- Commercial execution risks include product uptake, payer access, pricing and rebates, and dependence on a limited number of specialty distributors and pharmacies. The three largest customers accounted for 55%, 21%, and 13% of Q3 product sales and approximately 89% of receivables combined. The company relies on third-party manufacturers and suppliers; replacement sources require regulatory qualification.
- Other notable items: $4 million paid to Elanco upon first commercial sale and recorded as an intangible asset, amortized over 10 years; Q3 and nine-month royalty expense to Elanco was $0.1 million. No material legal proceedings or material changes to previously disclosed risk factors were reported.
Important facts for investors to verify
- Subsequent XDEMVY prescriptions, net sales, gross-to-net deductions, inventory availability, and progress toward commercial and Medicare coverage.
- Whether commercial uptake and future revenue support management’s stated cash runway, given $78.2 million of nine-month operating cash use and ongoing losses.
- Conditions, deadlines, and costs associated with the remaining credit-facility tranches, including interest-rate exposure and debt repayment terms.
- Updated timelines and results for the Ersa, Galatea, and Carpo trials, and any resulting development or regulatory decisions.
- Customer concentration, third-party manufacturing reliability, and any changes in product returns, rebates, chargebacks, or other sales deductions.